Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
Merck (MRK) drops as full-year forecast misses consensus
February 2, 2023 6:51 AM EST(Updated - February 2, 2023 1:20 PM EST)
Shares of Merck (NYSE: MRK) tumbled more than 4% Thursday despite the New Jersey-based pharmaceutical giant reporting stronger-than-expected FQ4 results.
Merck reported Q4 EPS of $1.62 on revenue of $13.8 billion, beating the consensus for earnings of $1.53 on revenue of $13.65B. Molnupiravir sales fell 13% year-over-year to $825 million, still much higher than the consensus of $376M. Keytruda sales rose 19% to $5.45B, in line with the analyst... More
